Wir arbeiten zusammen, um den Krebs zu überlisten.
Team
Gilles Wainrib, PhD
Co-founder and Chief Scientific Officer
Thomas Clozel, MD
Co-founder and Chief Executive Officer
Jean-Frédéric Petit-Nivard
Chief Commercial Officer
Meriem Sefta
Chief Diagnostics Officer
Joseph Lehár, PhD
SVP Strategy & Business Development
Vassili Soumelis, MD, PhD
Chief Medical Officer
Darius Meadon
Chief Marketing Officer
May Kang Yu
SVP Finance
Anna Huyghues-Despointes
Chief Corporate Development Officer
Hubert Chaperon
Chief Operating Officer
Mariabrisa Olivares
Chief People Officer
Mathieu Galtier
Chief Data and Platform Officer
Yedidia Levy-Zauberman
SVP, Head of Public Affairs and Impact
Alban de La Sablière
Chief Business Officer
Jean-Philippe Vert
Chief R&D Officer
Wissenschaftlicher Beirat
Prof. Miriam Merad, MD, PhD (Chairwoman)
Direktor des Instituts für Präzisionsimmunologie an der Mount Sinai School of Medicine in New York
Linkedin
Prof. Olivier Elemento, MD, PhD
Director am Caryl and Israel Englander Institute for Precision Medicine der Cornell University
Linkedin
Prof. Jean-Yves Blay, MD, PhD
Generaldirektor am Centre Léon Bérard & Unicancer-University Claude Bernard
Linkedin
Jakob Nikolas Kather, MD, MSc
Professor für Klinische Künstliche Intelligenz Else Kröner Fresenius Zentrum für Digitale Gesundheit am Technische Universität Dresden
Linkedin
Prof. Fabrice André, MD, PhD
Forscchungsleiter am Gustave Roussy, Präsident der ESMO 2025-2026
Linkedin
Roger Stupp, MD
Leiter der Neuroonkologischen Abteilung und Professor of Neurological Surgery am Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine
Affiliation
Direktorium
